1. 1. J Ultrasound. 2011 Jun; 14(2): 84–88. Published online 2011 Apr 22. doi: 10.1016/j.jus.2011.04.006 Ganglioneuroblastoma: Case report and review of the literature S. Alessi, M. Grignani, and L. Carone (http://dx.doi.org/10.1016%2Fj.jus.2011.04.006#_blank) 2. J Korean Neurosurg Soc. 2015 Mar;57(3):211-214. English. Published online March 20, 2015. (http://dx.doi.org/10.1016%2Fj.jus.2011.04.006#_blank)http://dx.doi.org/10.3340/jkns.2015.57.3.211A Malignant Transformation of a Spinal Epidural Mass from Ganglioneuroblastoma to Neuroblastoma Mehmet Osman Akcakaya, M.D., Bilge Bilgic, M.D., Yavuz Aras, M.D., and Nail Izgi, M.D. (http://dx.doi.org/10.3340/jkns.2015.57.3.211) 3. Asian Spine J. 2014 Feb;8(1):74-78. English. Published online February 06, 2014. (http://dx.doi.org/10.3340/jkns.2015.57.3.211)http://dx.doi.org/10.4184/asj.2014.8.1.74 Cervical Symmetric Dumbbell Ganglioneuromas Causing Severe Paresis Akira Hioki, Kei Miyamoto, Yoshinobu Hirose, Yusuke Kito, Kazunari Fushimi, and Katsuji Shimizu (http://dx.doi.org/10.4184/asj.2014.8.1.74) 4. Weiss SW, Goldblum JR. Enzinger and Weiss"s Soft Tissue Tumors. ed 5. Weiss SW, Goldblum JRPhiladelphia: Mosby Elsevier; 2008. pp. 945-987. (http://dx.doi.org/10.4184/asj.2014.8.1.74) 5. Steele M, Jones NL, Ng V, et al.: Successful liver transplantation in an infant with stage 4S (M) neuroblastoma. Pediatr Blood Cancer 60 (3): 51-57, 2013. (http://dx.doi.org/10.4184/asj.2014.8.1.74) 6. De Bernardi B, Gerrard M, Boni L, et al.: Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 27 (7): 1034-40, 2009. (http://dx.doi.org/10.4184/asj.2014.8.1.74) 7. Strother DR, London WB, Schmidt ML, et al.: Outcome after surgery alone or with restricted use of chemotherapy for patients with lowrisk neuroblastoma: results of Children"s Oncology Group study P9641. J Clin Oncol 30 (15): 18428, 2012. (http://dx.doi.org/10.4184/asj.2014.8.1.74) 8. Iehara T, Hamazaki M, Tajiri T, et al.: Successful treatment of infants with localized neuroblastoma based on their MYCN status. Int J Clin Oncol 18 (3): 389-95, 2013. (http://dx.doi.org/10.4184/asj.2014.8.1.74) 9. Bagatell R, BeckPopovic M, London WB, et al.: Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol 27 (3): 365- 70, 2009 (http://dx.doi.org/10.4184/asj.2014.8.1.74) 10. Wendy B. London, Christopher N. Frantz, Laura A. Campbell, Robert C. Seeger, Babette A. Brumback, Susan L. Cohn, Katherine K. Matthay, Robert P. Castleberry, and Lisa Diller Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children’s Oncology Group Study (http://dx.doi.org/10.4184/asj.2014.8.1.74) 11. Houghton PJ, Cheshire PJ, Myers L, et al: Evaluation of 9-dimethylaminomethyl-10- hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229-239, 1992 (http://dx.doi.org/10.4184/asj.2014.8.1.74) 12. Zamboni WC, Stewart CF, Thompson J, et al: Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505-511, 1998 (http://dx.doi.org/10.4184/asj.2014.8.1.74) 13. Mattern MR, Hofmann GA, Polsky RM, et al: In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 5:467-474, 1993 (http://dx.doi.org/10.4184/asj.2014.8.1.74) 14. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. Children"s Cancer Group. N Engl J Med 341:1165-1173, 1999 (http://dx.doi.org/10.4184/asj.2014.8.1.74) 15. В.К. Бояршинов, И.С. Долгополов., Р.С. Равшанова, Г.Л. Менткевич НИИ детской онкологии и гематологии ГУ РОНЦ РАМН. Выоскодозная химиотерапия с трансплантацией гемопоэтических стволовых клеток в лечении нейробластомы высокого риска. (http://dx.doi.org/10.4184/asj.2014.8.1.74) 16. Matthay KK: Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 3:72-77, 1999 (http://dx.doi.org/10.4184/asj.2014.8.1.74)